Published DateClear

Start Date

End Date

Category

• Pipeline2

Organizations

• Bausch + Lomb72
• Eyes On Eyecare55
• Alcon, Inc.49
• American Optometric Association38
• Harrow32
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Aldeyra Therapeutics21
• Coopervision19

Tags

• Clinical Trials2
• Dry Eye2
• Dry Eye Disease2
• Eye Drops1

• Organizations: HanAll Biopharma✕

Clear all

Pipeline

HanAll Biopharma kicks off phase 3 DED trial on topical anti-inflammatory

VELOS-4 trial is evaluating tanfanerept for improvement in Schirmer test following last year’s phase 3 primary endpoint miss.

Pipeline

Tanfanercept fails DED phase 3 trial primary endpoints

HanAll Biopharma reports highly statistically significant improvement in secondary measures of VELOS-3 study.